Sparton Corporation

Sparton — Q3 FY2013 Earnings Presentation

13 slides from Sparton's earnings presentation, May 8, 2013

  1. Slide 1: Fiscal 2013 Third Quarter Financial Results Conference Call

    Exhibit 99.2 Fiscal 2013 Third Quarter Financial Results Conference Call May 8, 2013

  2. Slide 2: Safe Harbor Statement

    Safe Harbor Statement Certain statements herein constitute forward-looking statements within the meaning of the Securities Act of 1933, as amended and the Securities Exchange Act of 1934, as amended. When used herein, words such as “believe,” “expect,” “anticipate,” “project,” “plan,” “estimate,” “w

  3. Slide 3: Today's Agenda

    Today’s Agenda • 3rd Quarter Highlights • Fiscal 2013 YTD Financial Results • 3rd Quarter Segmented Operating Results • Liquidity & Capital Resources • Outlook • Q&A 3

  4. Slide 4: 3rd Quarter Highlights

    3rd Quarter Highlights • Awarded 18 new business programs during the third quarter of fiscal 2013 with estimated annual revenue of $11.3 million. • Sales backlog of approximately $208.8 million, including approximately $32.2 million from the Company’s newly acquired business; a 42% increase over a y

  5. Slide 5: Consolidated Financial Results

    Consolidated Financial Results Fiscal 2013 YTD (Reported) (Adjusted) (Adjusted) (Adjusted) (Adjusted) 9 months ended Mar. 31, 9 months ended Mar. 31, Total YoY Legacy YoY Onyx 2013 2012 2013 2012 Variance Variance Net Sales $ 178,879 $ 162,251 $ 178,879 $ 162,251 $ 16,628 $ 18,089 $ (1,461) Gross Pr

  6. Slide 6: Consolidated Financial Results

    Consolidated Financial Results Adjusted EBITDA 9 months ended Mar. 31, YoY 2013 2012 Variance Net Income $ 6,837 $ 5,456 $ 1,381 Interest expense 390 522 (132) Interest income (99) (73) (26) Provision for income taxes 271 3,046 (2,775) Depreciation and amortization 3,036 1,272 1,764 Restructuring/im

  7. Slide 7: Sales Results

    Sales Results Medical SALES (with Onyx) 3 Months Ended March 31, 9 Months Ended March 31, SEGMENT 2013 % of Total 2012 % Change 2013 % of Total 2012 % Change Medical (with Onyx) $ 39,139 61% $ 27,046 45% $ 102,002 57% $ 82,533 24% Complex Systems $ 16,482 26% $ 12,812 29% $ 42,888 24% $ 37,921 13% D

  8. Slide 8: Gross Profit Results

    Gross Profit Results Medical ADJUSTED GROSS MARGIN (with Onyx) 3 Months Ended March 31, 9 Months Ended March 31, SEGMENT 2013 GP % 2012 GP % 2013 GP % 2012 GP % Medical (with Onyx) $ 5,339 13.6% $ 3,593 13.3% $ 14,443 14.2% $ 11,090 13.4% Complex Systems 1,890 11.5% 933 7.3% 4,414 10.3% 3,327 8.8% D

  9. Slide 9: Sales & Gross Profit Results

    Sales & Gross Profit Results Complex Systems SALES 3 Months Ended March 31, 9 Months Ended March 31, SEGMENT 2013 % of Total 2012 % Change 2013 % of Total 2012 % Change Medical (with Onyx) $ 39,139 61% $ 27,046 45% $ 102,002 57% $ 82,533 24% Complex Systems 16,482 26% 12,812 29% 42,888 24% 37,921 13

  10. Slide 10: Sales & Gross Profit Results

    Sales & Gross Profit Results Defense & Security Systems SALES 3 Months Ended March 31, 9 Months Ended March 31, SEGMENT 2013 % of Total 2012 % Change 2013 % of Total 2012 % Change Medical (with Onyx) $ 39,139 61% $ 27,046 45% $ 102,002 57% $ 82,533 24% Complex Systems 16,482 26% 12,812 29% 42,888 24

  11. Slide 11: Liquidity & Capital Resources

    Liquidity & Capital Resources 50,000 0.45 Cash Availability 0.42 ($ in '000) Mar-12 Jun-12 Sep-12 Dec-12 Mar-12 0.4 Cash and equivalents 26,682 46,950 43,096 6,066 4,358 LOC Availability 16,469 16,277 16,012 51,000 52,000 0.35 Total 43,151 63,227 59,108 57,066 56,358 0.3 0.25 Debt 25,000 22,959 ($ i

  12. Slide 12: Fiscal 2013 Outlook

    Fiscal 2013 Outlook • Implementation of the strategic growth plan – Continue to gain traction on a nationally focused direct selling effort – Further leverage Viet Nam as a low cost country alternative and in-region provider – Maintain our level of investment in internal research & development to co

  13. Slide 13: Q&A

    CA) @) Sparton Q&A 13

Sparton — Q3 FY2013 Earnings Presentation on 6ix